-
Tytuł:
-
A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition.
-
Autorzy:
-
Dieterle ME; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Haslwanter D; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Bortz RH 3rd; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Wirchnianski AS; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.; Department of Biochemistry, Albert Einstein College of Medicine, New York, NY 10461, USA.
Lasso G; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Vergnolle O; Department of Biochemistry, Albert Einstein College of Medicine, New York, NY 10461, USA.
Abbasi SA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Fels JM; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Laudermilch E; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Florez C; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.; Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, NY 10996, USA.
Mengotto A; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10461, USA.
Kimmel D; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10461, USA.
Malonis RJ; Department of Biochemistry, Albert Einstein College of Medicine, New York, NY 10461, USA.
Georgiev G; Department of Biochemistry, Albert Einstein College of Medicine, New York, NY 10461, USA.
Quiroz J; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10461, USA.
Barnhill J; Department of Chemistry and Life Science, United States Military Academy at West Point, West Point, NY 10996, USA.
Pirofski LA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10461, USA.
Daily JP; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10461, USA.
Dye JM; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Lai JR; Department of Biochemistry, Albert Einstein College of Medicine, New York, NY 10461, USA.
Herbert AS; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.; The Geneva Foundation, 917 Pacific Avenue, Tacoma, WA 98402, USA.
Chandran K; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
Jangra RK; Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.
-
Źródło:
-
BioRxiv : the preprint server for biology [bioRxiv] 2020 May 20. Date of Electronic Publication: 2020 May 20.
-
Typ publikacji:
-
Preprint
-
Język:
-
English
-
References:
-
Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645)
Nat Med. 2020 Jul;26(7):1033-1036. (PMID: 32398876)
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8388-92. (PMID: 7667300)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446. (PMID: 32215622)
Curr Protoc Microbiol. 2020 Jun;57(1):e100. (PMID: 32302069)
J Virol. 2010 Jan;84(1):163-75. (PMID: 19846533)
Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
Virology. 2008 Jun 20;376(1):165-72. (PMID: 18396306)
Antiviral Res. 2018 Feb;150:30-38. (PMID: 29246504)
Front Microbiol. 2019 Apr 26;10:856. (PMID: 31105663)
J Virol. 2003 Aug;77(16):8801-11. (PMID: 12885899)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Nat Med. 2020 Sep;26(9):1422-1427. (PMID: 32651581)
Nature. 2018 Nov;563(7732):559-563. (PMID: 30464266)
Cell. 2020 Jul 9;182(1):73-84.e16. (PMID: 32425270)
Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169)
Nature. 2020 May;581(7807):221-224. (PMID: 32225175)
Science. 2020 Aug 21;369(6506):956-963. (PMID: 32540903)
Nat Microbiol. 2020 Apr;5(4):562-569. (PMID: 32094589)
J Med Virol. 2006 Dec;78(12):1509-12. (PMID: 17063504)
Adv Exp Med Biol. 2006;581:293-6. (PMID: 17037546)
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734. (PMID: 32376634)
J Clin Invest. 2020 Apr 1;130(4):1545-1548. (PMID: 32167489)
Science. 2020 Jun 12;368(6496):1274-1278. (PMID: 32404477)
Science. 2013 Apr 26;340(6131):479-83. (PMID: 23519211)
Emerg Microbes Infect. 2020 Dec;9(1):2105-2113. (PMID: 32893735)
Virology. 2005 Sep 30;340(2):174-82. (PMID: 16043204)
Nat Commun. 2020 Apr 24;11(1):2070. (PMID: 32332765)
Emerg Microbes Infect. 2020 Dec;9(1):680-686. (PMID: 32207377)
Mol Ther Nucleic Acids. 2016 May 24;5:e321. (PMID: 27219515)
mBio. 2015 Jun 30;6(4):e00801. (PMID: 26126854)
Nat Commun. 2020 Mar 27;11(1):1620. (PMID: 32221306)
J Med Virol. 2020 Sep;92(9):1609-1614. (PMID: 32275081)
Cell Host Microbe. 2017 Nov 8;22(5):688-696.e5. (PMID: 29120745)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Cell. 2020 May 14;181(4):894-904.e9. (PMID: 32275855)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
-
Grant Information:
-
R01 AI123654 United States AI NIAID NIH HHS; R01 AI132633 United States AI NIAID NIH HHS; R01 AI125462 United States AI NIAID NIH HHS; T32 GM007288 United States GM NIGMS NIH HHS; U19 AI142777 United States AI NIAID NIH HHS; R21 AI141367 United States AI NIAID NIH HHS; R01 AI143453 United States AI NIAID NIH HHS
-
Entry Date(s):
-
Date Created: 20200609 Latest Revision: 20240328
-
Update Code:
-
20240329
-
PubMed Central ID:
-
PMC7263493
-
DOI:
-
10.1101/2020.05.20.105247
-
PMID:
-
32511365
There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, and define correlates of immune protection, and to down-select candidate antivirals. Here, we describe a highly infectious recombinant vesicular stomatitis virus bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein that closely resembles the authentic agent in its entry-related properties. We show that the neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S and that neutralization of the rVSV and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific vaccines and therapeutics and for mechanistic studies of viral entry and its inhibition.
Update in: Cell Host Microbe. 2020 Jul 3;:. (PMID: 32738193)
